Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • Telemedicine BW
    • MDR & IVDR

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 10/01/2011 13256_de.jpg

    Review: What does the cell factory of the future look like?

    A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production.

    https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
  • Article - 03/12/2010 13135_de.jpg

    Review: Science meets Business Day 2010 (part II)

    How can plant physiologists and seed developers work together to achieve an understanding of the processes happening in the germinating plant embryo in order to improve the seed quality of sugar beet? How can virologists find new ways to switch off the flu virus and develop a marketable vaccine in cooperation with industrial partners?

    https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-ii
  • Dossier - 29/11/2010 Broken ampoule

    Drug safety and the difficulty of making ends meet

    Everybody wants safe drugs – manufacturers, doctors and patients. However, many dangers, both avoidable and unavoidable, make medicinal treatment a high-risk process, despite all best efforts and assertions. Not enough information on drug-related risks is available, and the estimated number of adverse drug reactions that go unreported is quite high.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/drug-safety-and-the-difficulty-of-making-ends-meet
  • Article - 29/11/2010 12175_de.jpg

    Against chronic liver inflammation and liver cancer

    Chronic hepatitis B and C are the major causes of liver cancer. In contrast to hepatitis B viruses, there is no hepatitis C virus vaccination available. New research carried out by Professor Bartenschlager and his colleagues from Heidelberg might give rise to new strategies for the development of vaccines and medications for the prevention and treatment of chronic hepatitis C virus infections.

    https://www.gesundheitsindustrie-bw.de/en/article/news/against-chronic-liver-inflammation-and-liver-cancer
  • Press release - 21/09/2010 Immatics Logo

    immatics raises 54 million euros to advance its late stage clinical therapeutic cancer vaccine portfolio

    immatics biotechnologies GmbH a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer announced today that it has raised 53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics existing pipeline of advanced therapeutic cancer vaccine candidates.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-raises-54-million-euros-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine-portf
  • Press release - 09/09/2010 China medical city logo

    China Medical City, Taizhou

    Taizhou is a commercial and industrial city of around 5 million inhabitants located in the Yantze River Delta about half way between Nanjing and Suzhou. Within the Taizhou city boundaries on a total area of 25 square kilometers China Medical City CMC a national-level pharmaceutical high-tech park is currently under construction.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/china-medical-city-taizhou
  • Press release - 08/09/2010

    Prevention and Treatment of Chronic Hepatitis C

    GENOVAC and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-and-treatment-of-chronic-hepatitis-c
  • Article - 30/08/2010 12172_de.jpg

    Diagnostics for the early detection of cervical cancer

    The Pap test is regarded as the most successful test for cancer ever, and has saved the lives of many women. However, the test is associated with several weaknesses. The Heidelberg-based in vitro diagnostics company mtm laboratories AG develops and commercialises highly sensitive and highly specific immunochemical tests that provide greater reliability. These tests have the potential to revolutionise the early detection of cervical cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/diagnostics-for-the-early-detection-of-cervical-cancer
  • Article - 23/08/2010 12137_de.jpg

    Antibiotics for the prevention of malaria

    Researchers from Heidelberg and Berlin have shown that if malaria-infected mice are administered an antibiotic, no parasites appear in the blood and the mice are protected from this life-threatening disease. The scientists believe that antibiotics also have the potential to strengthen the human immune system as well as making it possible to provide a natural needle-free vaccination against malaria.

    https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotics-for-the-prevention-of-malaria
  • Press release - 02/08/2010 11890_de.jpg

    GMP Centre established in Tübingen

    The Good Manufacturing Practice Zentrum GMP-Zentrum GMP Centre of Tübingen University Hospital was officially opened on 16th July. The GMP-Zentrum was established to enable the production of individualised vaccines and antibodies according to the rules of good pharmaceutical practice for the treatment of cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gmp-centre-established-in-tuebingen
  • Press release - 21/07/2010 11876_de.jpg

    One Million for Cancer Research from Manfred Lautenschläger Foundation

    When Harald zur Hausen was awarded the Nobel Prize for Medicine in 2008, Manfred Lautenschläger spontaneously offered to support the Nobel laureate’s scientific work by funding a new research team. These funds will now go to Angelika Riemer, a young scientist who plans to advance the development of a vaccine which is able to cure existing infections with carcinogenic human papillomaviruses at the German Cancer Research Center (Deutsches…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-million-for-cancer-research-from-manfred-lautenschlaeger-foundation
  • Press release - 22/06/2010

    CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer

    CureVac GmbH, the mRNA company, today announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer (NSCLC).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-iia-with-mrna-immunotherapeutic-in-non-small-cell-lung-cancer
  • Dossier - 14/06/2010 11484_de.jpg

    Engineers of life

    Synthetic biology focuses on the development of biological systems with new defined characteristics assembled according to the principles of engineering. Synthetic biology has the potential to be used for a broad range of applications and has solutions in store for major problems of the future. It also fuels fears that human beings are playing the role of creators and going beyond natural boundaries.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/engineers-of-life
  • Press release - 02/06/2010

    immatics enters Collaboration with the National Cancer Institute (NCI)

    immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-enters-collaboration-with-the-national-cancer-institute-nci
  • Article - 24/05/2010 View into an opened chicken egg. A tumour, applied to the outer membrane, which is criss-crossed with numerous blood vessels, has grown in a spherical area.<br />

    Alternative CAM: chicken eggs to precede mouse experiments

    Researchers who test whether in vitro results can be transferred to living organisms prefer to use mice rats or rabbits. Many questions can be answered using the chorioallantoic membrane CAM of fertilised chicken eggs an alternative model to animal experiments that provides rapid results and only costs 50 cents per egg.

    https://www.gesundheitsindustrie-bw.de/en/article/news/alternative-cam-chicken-eggs-to-precede-mouse-experiments
  • Press release - 21/05/2010 11423_de.jpg

    The road to individualized tumour vaccines

    What are the typical cancer cell characteristics that our immune system is directed against? Using a new biochemical method, scientists from the Neurosurgery Department of the Heidelberg University Hospital and the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) are now able to answer this question for each individual patient. The method is expected to help identify new target structures for individualized tumour vaccines.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-road-to-individualized-tumour-vaccines
  • Press release - 12/05/2010 07777_de.jpg

    CureVac raises EUR 27.6 Million in Financing Round

    CureVac GmbH, the mRNA vaccine company, today announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-eur-27-6-million-in-financing-round
  • Article - 29/04/2010 VFA_4C.jpg

    The biopharmaceutical industry remained stable in times of crisis

    The German biopharmaceutical industry has come through 2009 without experiencing too many major slumps. The roaring growth of the biopharmaceutical industry in previous years has been replaced by more moderate growth. This is the result published by the 4th Medical Biotechnology report in 2010 compiled on behalf of the biotech interest group of the vfa bio Association of Research-Oriented Pharmaceutical Companies by the Boston Consulting Group.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-biopharmaceutical-industry-remained-stable-in-times-of-crisis
  • Article - 19/04/2010 Scientist in the laboratory of Przybylski's reserach group at the University of Constance holding a test tube in her hand and standing in front of an analysis device.

    Natural antibodies to treat Alzheimer’s

    Alzheimers disease is characterised by changes in the substance and structure of the brain that are caused by the depositing of protein plaques in the brain. Prof. Michael Przybylski and his team of researchers at the University of Constance have deciphered the structure of the site where mouse antibodies attach to the plaques subsequently causing them to dissolve. These findings will now be used to identify the binding structure of a component…

    https://www.gesundheitsindustrie-bw.de/en/article/news/natural-antibodies-to-treat-alzheimer-s
  • Article - 26/03/2010 10970_de.jpg

    How do killer cells manage to survive?

    It is not easy for the body to protect itself once a virus has broken through the body’s lines of defence and caused a chronic infection. This task is made even more difficult when the intruders are viral hepatitis pathogens that attack the liver, the place where immunological tolerance is induced. Jörg Reimann (physician) and Reinhold Schirmbeck (biologist) are working on the development of T-cell-mediated therapeutic vaccination strategies to…

    https://www.gesundheitsindustrie-bw.de/en/article/news/how-do-killer-cells-manage-to-survive
  • Article - 18/03/2010 The photo shows a Y-shaped molecule. The major branch is shown in red and the other two in yellow.<br />

    Cancer treatment adapted to individual patient requirements

    There is still no treatment available for a number of non-Hodgkin B-cell lymphomas. Chemotherapy, which is the standard method of treating the lymphomas, has unpleasant side effects. Researchers led by Prof. Dr. Hendrik Veelken at the Freiburg University Medical Centre in cooperation with Freiburg-based CellGenix Technologie Transfer GmbH have developed a promising new treatment strategy. Results of the Phase I and the Phase II study, which has…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-treatment-adapted-to-individual-patient-requirements
  • Article - 15/03/2010 10460_de.jpg

    Innovative navigation system enables gene shuttles to reach their destination

    If everything goes to plan the Department of Gene Therapy at the University of Ulm will soon lose a work group to industry. Florian Kreppels team plans to turn a particular technology into hard cash using a method that can do something other gene shuttles are unable to do namely transport their freight to a specific destination.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-navigation-system-enables-gene-shuttles-to-reach-their-destination
  • Article - 15/03/2010 10701_de.jpg

    Campaign to eradicate malaria

    After many decades, efforts to develop an effective vaccine against malaria have finally brought researchers closer to their goal. However, the goal of eradicating malaria completely can only be reached through a complex strategy, to which researchers from Heidelberg are making intensive contributions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/campaign-to-eradicate-malaria
  • Article - 15/03/2010 Human papillomaviruses - electron microscope photo

    The first active immunisations against cancer

    The first anti-cancer vaccines were developed to prevent women from becoming infected with papillomaviruses and to protect them against cervical cancer. The development of vaccines can be traced back to the work of Nobel Laureate Harald zur Hausen and his colleagues at the German Cancer Research Centre in Heidelberg. But more development is required in the field of anti-cancer vaccines and this is why researchers worldwide are working on vaccines…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-first-active-immunisations-against-cancer
  • Dossier - 15/03/2010 09298_de.jpg

    Vaccine development

    As the recent discussion on the pros and cons of swine flu vaccinations has shown vaccinations are not very popular in Germany. However people tend to forget that no other medical development has helped people to the same extent as immunisation with vaccines has done. Examples include the discovery of the cow pox vaccination by Edward Jenner in 1796 and all the programmes that have been set up by the Global Alliance for Vaccines and Immunisation…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccine-development
  • Article - 13/03/2010 10874_de.jpg

    Assembling life from building blocks?

    As part of its “Bioethics Forum”, the German Ethics Council recently held a meeting in Berlin to inform the public about the fundamentals of synthetic biology and potential ethical problems and consequences in terms of our ideas about life and mankind in general arising from the progress made in this new field of research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/assembling-life-from-building-blocks
  • Dossier - 22/02/2010 10749_de.jpg

    Respiratory disease - congestion in the respiratory system

    Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/respiratory-disease-congestion-in-the-respiratory-system
  • Press release - 04/02/2010 10640_de.jpg

    World Cancer Day: encouraging the prevention, detection and treatment of cancer

    World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
  • Article - 15/12/2009 10453_de.jpg

    Arming the immune system against cancer

    The theory that immune cells are able to attack tumours has long been a theory with only a minority of supporters. However, this theory is currently experiencing a renaissance. In the future, it might even be possible to specifically alter T-lymphocytes in order to improve their ability to identify and destroy certain tumour types. Prof. Dr. Hanspeter Pircher and his team at the Freiburg University Medical Centre are focusing on the development…

    https://www.gesundheitsindustrie-bw.de/en/article/news/arming-the-immune-system-against-cancer
  • Press release - 08/12/2009 10296_de.jpg

    Vaccination of honeybees against the Varroa mite is possible

    For the first time ever, honeybees were orally ‚vaccinated’ with a genetically engineered product that was later detected in the bloodsucking Varroa mite. This product is a DNA-plasmid that is normally used for man, horses, swine and also for fish. The inventor of this innovative DNA-vaccination system for bees is Matthias Giese, PhD, who launches his own Institute for Molecular Vaccines (IMV) in Heidelberg/Germany starting in 2010.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccination-of-honeybees-against-the-varroa-mite-is-possible
  • Article - 03/12/2009 10296_de.jpg

    Matthias Giese: DNA vaccine to combat worldwide honeybee deaths

    Varroa mites attach to the body of bees and weaken them by sucking hemolymph infecting them with viruses that are believed to be the cause of the mass death of European honeybee colonies. Matthias Giese of the Heidelberg-based Institute for Molecular Vaccines developed a DNA vaccine that might just lead to a breakthrough in the quest to get rid of the Varroa parasites. Giese tells us about his project in the following interview.

    https://www.gesundheitsindustrie-bw.de/en/article/news/matthias-giese-dna-vaccine-to-combat-worldwide-honeybee-deaths
  • Article - 14/11/2009 10116_de.jpg

    "A little naivety always helps"

    The biotech company CureVac based in Tuebingen is working on the development of a new tumour therapy based on RNA molecules. Dr. Ingmar Hoerr one of the scientists who founded CureVac tells Christoph Bächtle about the obstacles the young company had to overcome and the tough decisions that led to success. At the very start he tells us the company owes its origins to a huge dollop of luck.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-little-naivety-always-helps
  • Press release - 04/11/2009

    CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer

    CureVac GmbH, the mRNA vaccine company, today announced that the German authorities approved the start of the Phase IIa trial in Prostate Cancer after assessment of the first safety data of lead candidate CV9103, a RNActive®-derived mRNA vaccine. Results so far from the Phase I show CV9103 to be safe and well tolerated.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-launches-phase-iia-mrna-vaccine-trial-in-prostate-cancer
  • Press release - 12/10/2009

    Cancer Cells Suppress the Body’s Own Defense Mechanisms

    Cancer cells use tricks to evade the immune system. Thus, for example, they attract specific blood cells which suppress the body’s own defense mechanisms. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), collaborating with colleagues of the University Surgical Hospital in Heidelberg and an international research team, have investigated these processes in bowel cancer. The results of their research have now…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cells-suppress-the-body-s-own-defense-mechanisms
  • Press release - 12/10/2009

    Immatics appoints Carsten Reinhardt as Chief Medical Officer

    The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer
  • Press release - 24/09/2009

    Call for innovative technologies that address global health concerns

    The World Health Organization is seeking innovative technologies, in particular medical devices that offer solutions to global health concerns in low- and middle-income countries. The deadline for submission of proposals is January the 31st 2010.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/call-for-innovative-technologies-that-address-global-health-concerns
  • Article - 21/08/2009 09395_de.jpg

    Patenting and clinical trials go hand in hand

    Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…

    https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
  • Press release - 10/08/2009

    How do immune cells recognise infectious pathogens?

    Scientists of the University of Heidelberg and the German Cancer Research Centre have clarified the functional principles of an important receptor for bacterial infections: immune cells recognise bacterial and viral pathogens with a receptor known as toll-like receptor 9 (TLR9), which mediates biochemical reaction chains in order to fend off intruders. This discovery made by the Heidelberg researchers paves the way to develop new anti-infective…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-immune-cells-recognise-infectious-pathogens
  • Press release - 30/07/2009

    Boehringer Ingelheim set to outpace the market again

    After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
  • Press release - 30/07/2009

    Why do hepatitis virus infections become chronic?

    The German Research Foundation (DFG) has approved funding for a new research project at the Universities of Freiburg and Heidelberg. The researchers are working on improving our understanding of the mechanisms that lead to chronic virus infections: how do hepatitis viruses manage to evade immunological defence reactions and survive in the organism without damaging the organism?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-do-hepatitis-virus-infections-become-chronic
  • Article - 30/07/2009 09261_de.jpg

    Keeping as many valuable attachments as possible

    The goal of many projects focusing on the purification of recombinant proteins is to rapidly and effectively remove substances and side products that would compromise the quality and quantity of biopharmaceutical compounds. A consortium of industrial and scientific partners is currently focusing on a different step in the biopharmaceutical production process: the goal is to keep as many as possible of the drugs’ ‘attachments’. The project focuses…

    https://www.gesundheitsindustrie-bw.de/en/article/news/keeping-as-many-valuable-attachments-as-possible
  • Article - 14/07/2009 Dr. Marcus Groettrup holding a test tube and pipette.

    Tiny particles are a weapon against tumours

    Prostate carcinoma is one of the most common malignant diseases claiming more than 84000 lives per year in the EU and the United States. In cooperation with the University of Constance the Thurgau Biotechnology Institute BITg is working on ways to remove prostate carcinomas and other tumours that are difficult to treat by using tiny particles made of biologically degradable polyester. Prof. Dr. Marcus Groettrup and his team of researchers have…

    https://www.gesundheitsindustrie-bw.de/en/article/news/tiny-particles-are-a-weapon-against-tumours
  • Article - 02/07/2009 HCMV has been detected in a renal artery organ model. The electron microscope image clearly shows the spiky spherical pathogen.

    A virus that hides while it waits for an opportunity to replicate

    Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-virus-that-hides-while-it-waits-for-an-opportunity-to-replicate
  • Article - 10/06/2009 Portrait of Dr Dirk Linke

    Dirk Linke - a vaccine is ready - just in case

    There is a well-known saying: travel broadens the mind. This is not the only consequence of travel – the biochemist Dr. Dirk Linke from Tübingen travelled to India on holiday and brought back an idea for a new scientific project. Since his return, his idea, the possibility of developing a vaccine with a wide-ranging effect against some of the most frequent diarrhoea pathogens, has even generated financial backing from prominent supporters.

    https://www.gesundheitsindustrie-bw.de/en/article/news/dirk-linke-a-vaccine-is-ready-just-in-case
  • Press release - 28/05/2009 07777_de.jpg

    CureVac Begins Clinical Study with mRNA Vaccine

    CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
  • Article - 16/05/2009 Mature arbuscules with finely branched hyphae

    Mykotown Greentech AG uses mycorrhiza to keep plants going

    Mykotown Greentech AG offer mycorrhizal preparations that protect the plants against dehydration and bacteria. The fungi also enhance plant growth. The plants provide the natural soil fungi with carbon while the fungi help the plant to capture nutrients and liquids from the soil.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mykotown-greentech-ag-uses-mycorrhiza-to-keep-plants-going
  • Press release - 30/04/2009 08506_de.jpg

    In the tubular system of human cells

    Scientists from the Hygiene Institute at the Heidelberg University Hospital have succeeded for the first time ever in showing the three-dimensional architecture of the dengue virus replication and assembly sites in human cells. Their paper was recently published in the renowned journal “Cell Host & Microbes”.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/in-the-tubular-system-of-human-cells
  • Article - 02/02/2009

    CureVac enters premier biotech league with new cancer vaccine

    At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-enters-premier-biotech-league-with-new-cancer-vaccine
  • Press release - 14/01/2009

    IND Approval for CureVac

    CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ind-approval-for-curevac
  • Press release - 10/12/2008

    CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer

    The German regulatory authority has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive - derived mRNA vaccine CV9103. It will be tested in patients with hormone-refractory metastatic prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-to-start-first-mrna-vaccine-clinical-trial-in-prostate-cancer

Page 4 / 5

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search